Clinical trials: multiple sclerosis
Multiple Sclerosis
Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients
The investigators hypothesize that serum neurofilament-light chain (NfL) levels at baseline and decrease of the macular ganglion cell complex (GCC) thickness at one year vs.
- Trial name
- NFL OCT (NCT04860947)
- Testing
- Brain MRI, Spinal Cord MRI, Retinal imaging
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Multiple Sclerosis, Paralytic Stroke
Effect of I-TRAVLE Training on Arm Function in MS and Chronic Stroke Patients
Rationale: Approx. 80% of acute stroke patients suffer from acute hemiparesis. Stroke patients have not reached their full potential when they are discharged from hospital.
- Trial name
- NCT01918748
- Testing
- Haptic Master
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 30 people
- Sponsor
- Hasselt University
Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Cladribine Tablets as an Exit Therapy Strategy
The objective of the study is to evaluate the effectiveness of CladT, in terms of disease stability and safety, as the last treatment option in ageing MS patients vs treatment continuation and discontinuation This observational…
- Conditions
- Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- CLADREXIT (NCT06887426)
- Testing
- Cladribine
- Where
- France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Sclerosis
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
The primary objective of this expanded access program is to provide ocrelizumab as treatment for eligible participants with primary progressive multiple sclerosis (PPMS) before it is commercially available in the United States…
- Trial name
- NCT02807285
- Testing
- Ocrelizumab
- Where
- 56 sites in United States
- Sponsor
- Genentech, Inc.
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
The primary objective of the study is to assess the safety and tolerability of long-term treatment with BIIB019 (Daclizumab High Yield Process; DAC HYP) monotherapy in participants with relapsing remitting multiple sclerosis…
- Trial name
- EXTEND (NCT01797965)
- Testing
- BIIB019 (Daclizumab)
- Where
- 222 sites in United States, Argentina and 25 more
- Volunteers
- 1,501 people
- Sponsor
- Biogen
Multiple Sclerosis
The Effects of Focal Vibration on Spasticity in Multiple Sclerosis Patients
This trial consists of application of little devices (named Equistasi®) generating focal vibrations to treat spasticity in neurological patients, affected by multiple sclerosis.
- Trial name
- NCT02848898
- Testing
- Equistasi
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Federico II University
Multiple Sclerosis
Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis
OBJECTIVES: I. Determine by quantitative magnetic resonance imaging measurements the change in the total volume of brain parenchyma as well as its gray and white matter, T2 and enhanced T1 lesion volume, and the magnetization…
- Trial name
- NCT00006060
- Testing
- standard gadolinium contrast
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Primary Progressive Multiple Sclerosis, Primary Progressive MS
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
- Conditions
- Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS)
- Trial name
- NCT07840326
- Testing
- SUN-627
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sundance Biosciences, Inc.
Fatigue in Multiple Sclerosis
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
This study evaluated the effect of an individualized web-based physical training in fingolimod -treated patients.
- Trial name
- PACE (NCT01490840)
- Testing
- Physical exercise
- Where
- 32 sites in Germany
- Volunteers
- 178 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis
International multicenter, randomized, double-blind, double-masked, placebo-controlled study of efficacy and safety of BCD-132 (JSC BIOСAD, Russia) using an active reference drug (teriflunomide) for the treatment of patients with…
- Trial name
- NCT04056897
- Testing
- BCD-132, 125 mg, Teriflunomide, BCD-132, 500 mg
- Where
- Russia
- Volunteers
- 271 people
- Sponsor
- Biocad
Multiple Sclerosis
Multiple Sclerosis Produces Cardiovascular Subclinical Dysfunction
Multiple sclerosis (MS), debilitating disease involving primarily the central nervous system, may cause cardiovascular dysfunction, due to autonomous nervous system dysfunction, physical invalidity, increased oxidative stress…
- Trial name
- NCT03001284
- Testing
- NO intervention
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Carol Davila University of Medicine and Pharmacy
Multiple Sclerosis
A Study of the MIND Diet for Persons With Multiple Sclerosis
This study will assess the impact of a MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet on brain health and MS symptoms.
- Trial name
- NCT06992115
- Testing
- Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet, Small Group
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Tuberous Sclerosis Complex
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
The purpose of this study is to investigate the efficacy and safety of NPC-12Y gel compared with placebo for skin lesions associated with tuberous sclerosis.
- Trial name
- NCT05495425
- Testing
- NPC-12Y gel
- Where
- 5 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Nobelpharma
Clinically Isolated Syndrome, Radiologically Isolated Syndrome
Isoelectric Focusing of Tears in Children With Radiologically Isolated or Clinically Isolated Syndrome
The main gold of this study is to lead a multicentric, prospective study, to evaluate the diagnostic quality of tears in children with clinically isolated syndrome (CIS) and radiologically isolated syndrome (RIS) during a…
- Conditions
- Clinically Isolated Syndrome, Radiologically Isolated Syndrome, Multiple Sclerosis in Children
- Trial name
- OBIT (NCT03979391)
- Testing
- Tear collection and lumbar punction
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Lille Catholic University
Multiple Sclerosis
Sensory Integration Disorders in Patients With MS Including Disease Advancement and Relapses in the Last Year
the aim of the study was to assess the occurrence of sensory integration disorders in people with SI depending on the stage of the disease and relapses in the last year;analysis of sensory integration disorders in patients with…
- Trial name
- NCT05449574
- Testing
- Scale for the Assessment of Sensory Integration in Adults
- Where
- Poland
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Pomeranian Medical University Szczecin
Multiple Sclerosis
Resistance Training and Corticospinal Excitability in Multiple Sclerosis
The goal of the present study is to investigate effects of progressive resistance training on central nervous system functioning (corticospinal excitability (CSE)) and walking capacity in persons with multiple sclerosis (pwMS).
- Trial name
- NEXIMS (NCT06374108)
- Testing
- Progressive resistance training
- Where
- 2 sites in Denmark
- Volunteers
- 54 people
- Sponsor
- University of Aarhus
Multiple Sclerosis, Quality of Life (QOL)
Enhancing Self-Esteem in Patients With Multiple Sclerosis: A Randomised Controlled Trial of the Lexical Association Technique
The goal of this clinical trial is to learn whether the Lexical Association Technique (LAT) can improve well-being in people recently diagnosed with multiple sclerosis (MS), either relapsing-remitting (RRMS) or secondary…
- Trial name
- SE-P-MS (NCT07064291)
- Testing
- The Lexical Association Technique (LAT)
- Where
- France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Grenoble
Multiple Sclerosis, Clinically Isolated Syndrome
Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)
REFLEXION is a double blind extension of the study 27025 (NCT00404352) (REFLEX). The purpose of the study is to obtain long-term follow-up data in subjects with clinically definite multiple sclerosis (MS) and subjects with a…
- Trial name
- REFLEXION (NCT00813709)
- Testing
- RNF
- Where
- 57 sites in Argentina, Austria and 22 more
- Volunteers
- 402 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hereditary Ataxia, Multiple Sclerosis
Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia
Cerebellar disorders are often disabling and symptomatic therapies are limited to few options that are partially effective. It seems therefore appropriate to search for additional approaches.
- Conditions
- Hereditary Ataxia, Multiple Sclerosis, Cerebellar Ataxia
- Trial name
- NCT00202397
- Testing
- Riluzole
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- S. Andrea Hospital
Multiple Sclerosis, Relapsing-Remitting
A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)
The purpose of this study is to collect real-world data and to gain insights about long-term usage of ozanimod (Zeposia ®), its effect on well-defined outcome parameters comprising participant-relevant outcomes, as well as…
- Trial name
- OzEAN (NCT05335031)
- Testing
- Ozanimod
- Where
- Germany
- Volunteers
- 450 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.